-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Public Health and Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience powered by Apple
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Environmental Social Governance
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions powered by Apple
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSInstitute Report
Understanding Insulin Market Dynamics in Low and Middle Income Countries
Producers, Supply and Cost
Aug 26, 2021
The rising rate of diabetes globally, particularly in low- and middle-income countries (“LMICs”), represents a significant health and economic burden for all health system stakeholders, particularly people living with diabetes who need improved access to quality diabetes care. The development of a robust competitive marketplace for insulin (as well as associated products) is seen by many stakeholders as a critical requirement for improving patients’ affordable access to quality diabetes care. And yet, little is known about the insulin market dynamics in LMICs.
This report looks at the competitive landscape for insulin manufacturing in the 32 low- and middle-income countries where IQVIA audited data exist. As in the rest of the world, the three largest companies in this area (Eli Lilly, Novo Nordisk and Sanofi) account for the majority of insulin manufacturing. This report looks at the volume of insulins produced by these companies and others, and the cost to purchasers of those medicines. When other companies beyond these three hold more significant shares of the market, they may offer their insulins at lower costs. This report assesses where competition is effectively present and if there is an expected correlation to costs.
Key Messages
Insulin producers/suppliers- The majority of global insulin volume is produced by the three largest insulin makers globally: Eli Lilly, Novo Nordisk and Sanofi.
- There is a diverse mix of other insulin manufacturers in the 32 LMICs (low- and middle-income countries) studied, including large biosimilar manufacturers and other manufacturers (often operating in multiple countries) and many different distribution companies marketing insulin in LMICs.
- Across the 32 markets studied, the insulin supply situation is mixed: in 13 countries, companies other than the three largest have 31% of volume, while in the other 19 LMICs the three largest have significant share (>95%).
- The three largest companies’ share of human insulin volume is low in some large population countries: <20% in Philippines and Mexico, <40% in Malaysia and Russia), <60% in China and Vietnam, and <70% in India and Thailand.
- There is no correlation between the three largest companies’ market share and the average insulin cost per day.
- Insulin cost per day (at ex-manufacturer prices) is low across the 32 LMICs compared to developed markets, but has wide variations, with insulin analogs costing $0.78–1.73/day and human insulins costing $0.20–0.63/day.
- In 13 of the 32 markets where other (non-three largest) manufacturers have a significant presence, insulin costs per day average 21–33% lower for human insulin and 2–25% lower for insulin analogs than the larger companies’ costs in the same countries.
- However, in 19 of the 32 markets where the three largest have a very strong market presence (95+% volume market share), insulin analogs and human insulin costs per day are often lower than other LMIC countries, even in the absence of significant competition from other manufacturers.
Key Findings
- The majority of global insulin volume is produced by the three largest manufacturers: Eli Lilly, Novo Nordisk and Sanofi.
- Across all 32 LMICs, the three largest companies produce 83% of days of therapy measured in WHO-DDD.
- In 19 of the 32 LMICs studied, these three companies have more than 95% market share.
- In 13 other LMICs, other smaller companies average 31% of volume (and 22% of sales), including 27% of volume in China, 28% in India and 35% in 11 other LMIC countries.
- Human insulins account for 58% of the days of therapy for insulins across 32 LMICs and smaller companies represent 29% of human insulin volume as measured in days of therapy (WHO-DDD).
- Insulin analogs represent 42% of the use of insulins across 32 LMICs, with 92% of the volume produced by the three largest companies and 8% via other companies producing them as biosimilars.
- Human insulins have less complex manufacturing and lower costs than insulin analogs.
- Insulin analogs have risen to 42% of days of therapy, up from 25% in 2010.
- Insulin analogs averaged 15% growth over 10 years, compared to 7% growth for human insulins in the same period.
In addition to the three largest companies, the following companies market insulin in the LMICs surveyed, often in multiple countries:
- 12 large biosimilar manufacturers: Biocon, Bioton, Gan & Lee, Geropharm, Julphar, Kalbe Pharma, Kocak, Landsteiner, Lupin, Probiomed, Sedico and Wockhardt.
- 28 other manufacturers: ACI Limited, Aristopharma, Arterium, Ascendis, Baxter, Belmed, BJ Ganli, Denver Farma, Incepta Pharma, Koye Pharma, Kyowa Hakko Kirin, M.J. Biopharm, Medical Union, Medsyntez, Pharmevo, Popular Pharma, Sanbe, Shreya Group, Sothema, Square, Sun Pharma, Tarchomin ZF Polfa, Tianmai Biotech, Tonghua Dongbao, USV, Unilab and Zhuhai United Lab.
- These smaller manufacturers are often not vertically integrated and instead contract with approximately 50 distribution companies that are marketing insulin across these countries.
- In countries where the manufacturers other than the three largest have significant share of spending, there is some local manufacturing, primarily of human insulins, and to a lesser degree, insulin analog biosimilars.
- The number of companies manufacturing insulin is higher in countries with larger market opportunities.
- In two of the three countries where the three largest manufacturers do not have their own direct sale – Morocco and India – they support a local company that distributes their products.